News

Athens, 22 April 2024 – The first meeting of the new Board of Directors of SFEE was held today, and the new BoD was constituted into body as follows:

As President Mr. Olympios Papadimitriou, General Manager of Novo Nordisk Hellas, was elected.

Mr. Konstantinos Panagoulias, Vice-Chairman of the Board of Directors of VIANEX and General Manager of VIAN, was elected Deputy President and Vice President responsible for Financial Affairs, Development, Hospitals, Labor Affairs and Pricing.

The following were elected Vice-Presidents:

1. Elena Chouliara, responsible for Reimbursement, HTA, Negotiation and Pharmaceutical Expenditure (President and CEO of AstraZeneca) and Alternate Spyros Filiotis (Vice President and General Manager of Pharmaserve-Lilly),
2. Dimitris Anagnostakis, responsible for Scientific Affairs and Clinical Studies (President and CEO of Boehringer Ingelheim Greece & Cyprus) and Alternate Agata Jakoncic (President of MSD Greece, Cyprus and Malta).

Mr. Konstantinos Papagiannis (President and CEO of Novartis Hellas) was elected Secretary General and responsible for Data Monitoring issues.

Mr. Christos Sotiriou (Vice President and CEO of Win Medica) was elected Treasurer.

Members of the Board of Directors are:

1. Panagiotis Giannouleas (Chief Operating Officer & Country Manager of Lavipharm Group),
2. Kyriakos Berberian (General Manager of Genesis Pharma Greece, Cyprus & Malta),
3. Cornelia Zanetti (General Manager of Takeda Greece, Cyprus & Malta).

It is noted that the responsibility of the Communication and Public Affairs Committees remains with the President, while the responsibility of the Ethics and Transparency Committee, as well as the responsibility for communication with EFPIA, will continue to lie with the Director General of SFEE, Mr. Michael Himonas.

The new Board of Directors of SFEE focuses on four key priorities and will develop corresponding strategic actions and policies:

1. Boost funding and tackle excessive returns – Allocate resources more efficiently through digital tools and controls.
2. Patient access to innovative treatments.
3. Strengthening the pharmaceutical industry’s footprint in the national economy, through investments in production, research and development, collaborations between Greek and International companies and provision of services.
4. Revision of European Pharmaceutical Legislation.

The new President of SFEE, Mr. Olympios Papadimitriou, noted: “The new Board of Directors, renewed, continues the previous one’s effort to address significant challenges. The difference is that the time frame for creating a sustainable, predictable environment for the pharmaceutical industry has become unbearably short. The best way to address these challenges is for a united SFEE to work towards a unified and strong voice in the health sector, and to be an important partner of the State in health policy-making. Cooperation between government and industry is essential to achieve sustainable solutions that will serve the needs of society and the economy.”